Sonsalla P K, Gibb J W, Hanson G R
J Pharmacol Exp Ther. 1986 Sep;238(3):932-7.
Previous studies have demonstrated that the effects of methamphetamine (METH) on dopaminergic and serotonergic systems are likely related to METH-induced increases in dopamine release. The ability of haloperidol to prevent these effects of METH suggests that dopamine receptor activation is involved in mediating these METH actions. The present studies were undertaken to determine what role the dopamine receptor subtype(s) might have in such METH effects. We found that the D1 antagonist, SCH23390, attenuated or blocked the effects of METH on dopaminergic and serotonergic systems, whereas the D2 antagonist, sulpiride, blocked the effects of METH on only the dopaminergic system. The results of the present studies suggest that METH-induced increases in dopaminergic action on both D1 and D2 receptors are associated with the effects of METH on the dopaminergic system. In contrast, dopamine action on D1, but not on D2, receptors appears to be involved in the effects of METH on the serotonergic systems of the neostriatum and the cerebral cortex.
先前的研究表明,甲基苯丙胺(METH)对多巴胺能和5-羟色胺能系统的影响可能与METH诱导的多巴胺释放增加有关。氟哌啶醇预防METH这些作用的能力表明,多巴胺受体激活参与介导这些METH作用。进行本研究以确定多巴胺受体亚型在这种METH作用中可能起什么作用。我们发现,D1拮抗剂SCH23390减弱或阻断了METH对多巴胺能和5-羟色胺能系统的作用,而D2拮抗剂舒必利仅阻断了METH对多巴胺能系统的作用。本研究结果表明,METH诱导的对D1和D2受体的多巴胺能作用增加与METH对多巴胺能系统的作用有关。相比之下,多巴胺对D1受体而非D2受体的作用似乎参与了METH对新纹状体和大脑皮层5-羟色胺能系统的作用。